Alvotech and STADA Arzneimittel AG are strengthening their existing strategic alliance for high-quality, cost-effective biosimilars by extending their partnership to cover AVT03, a clinical-stage biosimilar candidate referencing the Prolia /Xgeva (denosumab) medicines for osteoporosis and cancer-related bone loss respectively. Alvotech's estimates of revenue, expenses and profitability; Alvotech's ability to develop, manufacture and commercialize the products and product candidates in its pipeline; the ability of Alvotech or its partners to enroll and retain patients in clinical studies; the ability of AlvoteCh or its partners to gain approval from regulators for planned clinical studies, study plans or sites; the ability of AlvoteCH's partners to conduct, supervise and monitor existing and potential future clinical studies, which may impact development timelines and plans; Alvotech's ability, and that of its commercial partners, to execute their commercialization strategy for approved products; Alvotech's ability. Alvotech's ability, and that of its commercialization strategy forapproved products; the outcome of ongoing and future litigation regarding Alvotech's products and product candidates; the impact of worsening macroeconomic conditions, including rising inflation and interest rates and general market conditions, conflicts in Ukraine, the Middle East and other global geopolitical tension, on the Company's business, financial position, strategy and anticipated milestones; Alvotech's ability To meet the conditions precedent to close Facility and comply with the covenants of the Facility and (ustekinumab).